These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17885539)

  • 21. The under-recognized role of dopamine in the treatment of major depressive disorder.
    Montgomery SA
    Int Clin Psychopharmacol; 2008 Mar; 23(2):63-9. PubMed ID: 18301120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Strawn JR; Mills JA; Croarkin PE
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
    [No Abstract]   [Full Text] [Related]  

  • 23. Antidepressant treatment strategy with an early onset of action improves the clinical outcome in patients with major depressive disorder and high anxiety: a multicenter and 6-week follow-up study.
    Liao XM; Su YA; Wang Y; Yu X; Si TM
    Chin Med J (Engl); 2020 Mar; 133(6):726-728. PubMed ID: 32097208
    [No Abstract]   [Full Text] [Related]  

  • 24. Serotonin-norepinephrine reuptake inhibitor treatment for tinnitus and depression.
    Chang JP; Wu CC
    J Clin Psychopharmacol; 2012 Oct; 32(5):729. PubMed ID: 22926618
    [No Abstract]   [Full Text] [Related]  

  • 25. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy.
    Leo R; Di Lorenzo G; Tesauro M; Razzini C; Forleo GB; Chiricolo G; Cola C; Zanasi M; Troisi A; Siracusano A; Lauro R; Romeo F
    J Clin Psychiatry; 2006 Nov; 67(11):1760-6. PubMed ID: 17196057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Introduction: the dual-action debate: does pharmacology matter?
    Thase ME
    J Clin Psychiatry; 2004; 65 Suppl 17():3-4. PubMed ID: 15600375
    [No Abstract]   [Full Text] [Related]  

  • 27. Autonomic reactivity to induced emotion as potential predictor of response to antidepressant treatment.
    Fraguas R; Marci C; Fava M; Iosifescu DV; Bankier B; Loh R; Dougherty DD
    Psychiatry Res; 2007 May; 151(1-2):169-72. PubMed ID: 17360044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder.
    Illi A; Setälä-Soikkeli E; Kampman O; Viikki M; Nuolivirta T; Poutanen O; Huhtala H; Mononen N; Lehtimäki T; Leinonen E
    Psychiatry Res; 2010 Mar; 176(1):85-7. PubMed ID: 20071037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autonomic neurocardiac function in patients with major depression and effects of antidepressive treatment with nefazodone.
    Agelink MW; Majewski T; Wurthmann C; Postert T; Linka T; Rotterdam S; Klieser E
    J Affect Disord; 2001 Feb; 62(3):187-98. PubMed ID: 11223106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sympathetic overactivity--the Cinderella of cardiovascular risk factors in dialysis patients.
    Vonend O; Rump LC; Ritz E
    Semin Dial; 2008; 21(4):326-30. PubMed ID: 18627567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmentation with atomoxetine in treatment-resistant depression with psychotic features. A case report.
    Pilhatsch MK; Burghardt R; Wandinger KP; Bauer M; Adli M
    Pharmacopsychiatry; 2006 Mar; 39(2):79-80. PubMed ID: 16555170
    [No Abstract]   [Full Text] [Related]  

  • 32. Should selective serotonin reuptake inhibitors be prescribed for children with major depressive and anxiety disorders?
    Safer DJ
    Pediatrics; 2006 Sep; 118(3):1248-51. PubMed ID: 16951019
    [No Abstract]   [Full Text] [Related]  

  • 33. Personalizing the care of geriatric depression.
    Alexopoulos GS
    Am J Psychiatry; 2008 Jul; 165(7):790-2. PubMed ID: 18593780
    [No Abstract]   [Full Text] [Related]  

  • 34. Selective serotonin reuptake inhibitors in adolescent depression still controversial.
    Holzer L; Baumann P
    J Clin Psychopharmacol; 2007 Jun; 27(3):325-6; author reply 326. PubMed ID: 17502798
    [No Abstract]   [Full Text] [Related]  

  • 35. Duloxetine treatment of social anxiety disorder with comorbid major depression.
    Lin CC
    J Clin Psychopharmacol; 2008 Oct; 28(5):591-2; author reply 592-3. PubMed ID: 18794669
    [No Abstract]   [Full Text] [Related]  

  • 36. Selective serotonin reuptake inhibitors in children and adolescents with major depression.
    Scahill L
    Braz J Psychiatry; 2005 Jun; 27(2):91-2. PubMed ID: 15962129
    [No Abstract]   [Full Text] [Related]  

  • 37. Selective serotonin reuptake inhibitor treatment of major depressive disorder in children and adolescents.
    Newcorn JH
    Curr Psychiatry Rep; 2004 Apr; 6(2):85-7. PubMed ID: 15038909
    [No Abstract]   [Full Text] [Related]  

  • 38. Increases in orbitofrontal cortex thickness following antidepressant treatment are associated with changes in resting state autonomic function in adolescents with major depression - Preliminary findings from a pilot study.
    Koenig J; Westlund Schreiner M; Klimes-Dougan B; Ubani B; Mueller BA; Lim KO; Kaess M; Cullen KR
    Psychiatry Res Neuroimaging; 2018 Nov; 281():35-42. PubMed ID: 30216863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute psychophysiologic reactivity and risk of cardiovascular disease: a review and methodologic critique.
    Krantz DS; Manuck SB
    Psychol Bull; 1984 Nov; 96(3):435-64. PubMed ID: 6393178
    [No Abstract]   [Full Text] [Related]  

  • 40. Cerebral perfusion response to successful treatment of depression with different serotoninergic agents.
    Vlassenko A; Sheline YI; Fischer K; Mintun MA
    J Neuropsychiatry Clin Neurosci; 2004; 16(3):360-3. PubMed ID: 15377745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.